Opportunity Information: Apply for PA 09 033
Apply for PA 09 033
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Research on the Cognitive Sequelae of Parkinsons Disease (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.361 Nursing Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.866 Aging Research.
- This funding opportunity was created on Dec 10, 2008 and posted on Dec 10, 2008.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: City or township governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Private institutions of higher education Special district governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Research on the Cognitive Sequelae of Parkinsons Disease (R01) funding opportunity (PA 09 033) is an NIH research grant announcement focused on the non-motor aspects of Parkinsons disease, especially problems involving thinking, memory, and other cognitive functions, as well as mood and emotional regulation. While Parkinsons is widely known for movement symptoms, this FOA highlights that cognitive impairment and affective disturbances (such as depression, anxiety, apathy, and related mood symptoms) are common, clinically significant, and often difficult to diagnose and treat. The opportunity is designed to support research that clarifies why these symptoms occur, how they progress, and how clinicians can better detect and treat them.
The participating NIH institutes for this announcement are the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR). The multi-institute sponsorship signals that the topic cuts across neurology, aging, mental health, and clinical care research, and that proposals can approach the problem from multiple angles, including basic neuroscience, translational studies, clinical research, and biobehavioral or nursing-related perspectives.
In terms of what the FOA is looking to fund, it centers on three broad research directions. First, it encourages studies of the underlying neurobiological mechanisms tied to cognitive impairment and mood disturbance in Parkinsons disease. That can include work aimed at understanding brain circuitry changes, neurotransmitter system involvement beyond dopamine, the role of comorbid pathologies (for example, overlapping Alzheimer-type or Lewy body-related processes), neuroinflammation, genetic and molecular contributors, or other mechanistic explanations that connect Parkinsons disease biology to changes in cognition and affect. The emphasis is on explaining the "why" and "how" behind these symptoms, rather than treating them as secondary complications.
Second, the FOA invites research on developing clinical interventions and therapeutics for cognitive impairment and affective symptoms in Parkinsons disease. This can include the testing or refinement of pharmacologic approaches, behavioral interventions, cognitive training or rehabilitation methods, neuromodulation strategies, psychotherapy adapted for PD populations, caregiver-supported interventions, or other therapeutic approaches aimed at improving cognitive performance, daily functioning, mood stability, or quality of life. The focus is not limited to any one type of treatment, as long as the work is scientifically rigorous and directly addresses cognitive and affective outcomes relevant to PD.
Third, it supports research intended to improve clinical diagnosis or treatment of cognitive and affective impairment in Parkinsons disease. That can mean developing or validating better screening tools, biomarkers, clinical assessment batteries, predictive models, or practical diagnostic methods that help clinicians identify cognitive decline or mood disorders earlier and more accurately. It can also involve improving treatment decision-making in real-world care settings, including how clinicians monitor symptoms over time or tailor interventions to specific patient subgroups. In other words, beyond discovering mechanisms and testing therapies, the FOA also prioritizes work that makes diagnosis and management more effective in everyday clinical practice.
A specific stated goal of the announcement is to push the field toward more cross-disciplinary and biobehavioral collaboration. The FOA explicitly aims to lower barriers that often keep basic scientists and clinicians working in separate lanes, and to encourage integrated approaches that examine cognition and affective regulation together in the context of Parkinsons disease diagnosis and treatment. This matters because cognitive and mood symptoms in PD are often intertwined, influenced by overlapping neural systems, medication effects, sleep disruption, autonomic symptoms, caregiver stress, and broader aging-related processes. The FOA frames these issues as requiring combined expertise across neuroscience, psychiatry, neurology, geriatrics, psychology, nursing, and related disciplines.
Administratively, this is a discretionary grant opportunity using the NIH R01 research project grant mechanism, which generally supports investigator-initiated, hypothesis-driven projects of substantial scope. The opportunity was posted on December 10, 2008, and the original and final closing date listed is January 7, 2012, with an archive date of February 7, 2012, meaning it is no longer open but remains as a reference point for the type of research NIH sought to stimulate in this area during that period. The announcement is associated with multiple CFDA program areas, including mental health research grants (93.242), nursing research (93.361), neurosciences and neurological disorders extramural research (93.853), and aging research (93.866), reinforcing the cross-cutting nature of the topic.
Eligibility is broad and includes many organization types, not just universities. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), for-profit organizations (other than small businesses and also including small businesses), and various government entities such as state governments, county governments, city or township governments, special district governments, and independent school districts. The eligibility language also explicitly includes a range of mission-focused institutions and communities such as Historically Black Colleges and Universities, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and certain tribal organizations and governments. It also notes that non-U.S. entities (foreign organizations) and regional organizations may be eligible, along with U.S. territories or possessions and faith-based or community-based organizations, depending on the specific NIH eligibility terms referenced in the full announcement. There is no cost sharing or matching requirement listed, which is typical for many NIH research grants.
The sponsoring agency is the National Institutes of Health, and the full announcement was made available through the NIH Grants Guide, with an additional information link directing applicants to the complete FOA text. For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster, indicating that procedural or web access questions were routed through NIH support rather than a single program officer contact in the excerpt provided.
Overall, this FOA is essentially a call for rigorous R01-level research that treats cognitive impairment and mood disturbance in Parkinsons disease as core clinical problems with identifiable biology and modifiable outcomes. It encourages projects that connect mechanistic neuroscience to practical clinical advances, with a strong preference for multidisciplinary work capable of improving how these symptoms are understood, detected, and treated.
Frequently Asked Questions (FAQs): Research on the Cognitive Sequelae of Parkinsons Disease (R01) (PA 09 033)
What is this funding opportunity?
This is an NIH research grant announcement titled "Research on the Cognitive Sequelae of Parkinsons Disease (R01)" (PA 09 033). It focuses on research into non-motor aspects of Parkinsons disease, particularly cognitive impairment (thinking, memory, and related functions) and affective or mood disturbances (such as depression, anxiety, and apathy).
What type of grant mechanism does this opportunity use?
The announcement uses the NIH R01 research project grant mechanism, which generally supports investigator-initiated, hypothesis-driven research projects of substantial scope.
Which agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Which NIH institutes participate in this announcement?
The participating NIH institutes are the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR).
What is the main scientific and clinical focus of the FOA?
The FOA targets cognitive impairment and affective disturbances in Parkinsons disease and emphasizes that these symptoms are common, clinically significant, and often difficult to diagnose and treat. It aims to support research that clarifies why these symptoms occur, how they progress, and how detection and treatment can be improved.
Why does this FOA emphasize non-motor symptoms in Parkinsons disease?
While Parkinsons disease is widely known for movement symptoms, the FOA highlights that cognitive and mood-related symptoms are also frequent and can substantially affect daily functioning and quality of life. The announcement treats these problems as core features with identifiable biology and potentially modifiable outcomes.
What major research directions does the FOA encourage?
The FOA centers on three broad directions: (1) studies of underlying neurobiological mechanisms tied to cognitive impairment and mood disturbance in Parkinsons disease, (2) development and testing of clinical interventions and therapeutics targeting cognitive and affective outcomes in Parkinsons disease, and (3) research to improve clinical diagnosis and treatment of cognitive and affective impairment in real-world practice.
What kinds of mechanistic research topics are responsive to this FOA?
The FOA encourages research into neurobiological mechanisms that may explain cognitive and affective symptoms in Parkinsons disease. Examples mentioned include brain circuitry changes, neurotransmitter system involvement beyond dopamine, comorbid pathologies (such as overlapping Alzheimer-type or Lewy body-related processes), neuroinflammation, and genetic or molecular contributors.
Does the FOA require projects to focus only on dopamine-related mechanisms?
No. The FOA explicitly notes interest in neurotransmitter system involvement beyond dopamine and encourages mechanistic explanations that connect Parkinsons disease biology to changes in cognition and affect.
Does the FOA consider overlapping or comorbid pathologies relevant?
Yes. The FOA specifically mentions comorbid pathologies, including overlapping Alzheimer-type or Lewy body-related processes, as examples of potential contributors to cognitive and affective impairment in Parkinsons disease.
What types of intervention research does the FOA invite?
The FOA invites rigorous research on clinical interventions and therapeutics for cognitive impairment and affective symptoms in Parkinsons disease. Examples include pharmacologic approaches, behavioral interventions, cognitive training or rehabilitation, neuromodulation strategies, psychotherapy adapted for Parkinsons populations, and caregiver-supported interventions.
Are non-pharmacologic approaches considered relevant under this FOA?
Yes. The FOA explicitly includes behavioral interventions, cognitive training or rehabilitation methods, psychotherapy adapted for Parkinsons disease populations, and caregiver-supported interventions as examples of responsive approaches.
Is the FOA limited to one kind of treatment strategy?
No. The FOA states that the focus is not limited to any one type of treatment, as long as the proposed work is scientifically rigorous and directly addresses cognitive and affective outcomes relevant to Parkinsons disease.
What does the FOA mean by improving clinical diagnosis or treatment?
This includes research to develop or validate improved screening tools, biomarkers, clinical assessment batteries, predictive models, or practical diagnostic methods to identify cognitive decline or mood disorders earlier and more accurately. It can also include work that improves how symptoms are monitored over time or how interventions are tailored to specific patient subgroups in real-world care settings.
Does the FOA support biomarker or screening tool development?
Yes. The FOA lists biomarkers and better screening tools among the types of research that could improve diagnosis and management of cognitive and affective impairment in Parkinsons disease.
Is cross-disciplinary collaboration emphasized?
Yes. A stated goal is to encourage cross-disciplinary and biobehavioral collaboration, reduce barriers between basic scientists and clinicians, and promote integrated approaches that examine cognition and affective regulation together in the context of Parkinsons disease diagnosis and treatment.
Why does the FOA encourage integrated approaches to cognition and mood in Parkinsons disease?
The FOA notes that cognitive and mood symptoms in Parkinsons disease are often intertwined and can be influenced by overlapping neural systems, medication effects, sleep disruption, autonomic symptoms, caregiver stress, and aging-related processes. Integrated expertise across disciplines is presented as important for meaningful advances.
Which disciplines or perspectives does the FOA suggest may be relevant?
The FOA frames the topic as spanning neuroscience, psychiatry, neurology, geriatrics, psychology, nursing, and related disciplines, and encourages approaches ranging from basic neuroscience to translational, clinical, biobehavioral, and nursing-related research.
Who is eligible to apply?
Eligibility is broad and includes many organization types. Eligible applicants include public and private institutions of higher education; nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status); for-profit organizations (including small businesses); and government entities such as state, county, and city or township governments, special district governments, and independent school districts.
Are mission-focused institutions and underrepresented community-serving organizations included in eligibility?
Yes. The eligibility language explicitly includes Historically Black Colleges and Universities, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and certain tribal organizations and governments.
Are foreign (non-U.S.) organizations eligible?
The provided information states that non-U.S. entities (foreign organizations) and regional organizations may be eligible, along with U.S. territories or possessions, depending on the specific NIH eligibility terms referenced in the full announcement.
Are faith-based or community-based organizations eligible?
The provided information indicates that faith-based or community-based organizations may be eligible depending on the NIH eligibility terms referenced in the full announcement.
Is cost sharing or matching required?
No cost sharing or matching requirement is listed for this opportunity.
When was the opportunity posted and when did it close?
The opportunity was posted on December 10, 2008. The original and final closing date listed is January 7, 2012. The archive date is February 7, 2012.
Is this funding opportunity still open?
No. Based on the listed closing and archive dates, it is no longer open and remains available as an archived reference for the type of research NIH sought to stimulate during that period.
What program areas (CFDA) are associated with this FOA?
The announcement is associated with multiple CFDA program areas, including mental health research grants (93.242), nursing research (93.361), neurosciences and neurological disorders extramural research (93.853), and aging research (93.866).
Where was the full announcement made available?
The full announcement was made available through the NIH Grants Guide, and the excerpt references an additional information link directing applicants to the complete FOA text.
Who is listed as the contact for access or technical issues in the provided excerpt?
The contact listed for access or technical issues is the NIH Office of Extramural Research (OER) Webmaster, indicating that procedural or web access questions were routed through NIH support in the excerpt provided.
What is the overall purpose of this FOA in plain terms?
Overall, the FOA is a call for rigorous R01-level research that treats cognitive impairment and mood disturbance in Parkinsons disease as central clinical problems, encourages projects that connect mechanistic neuroscience to practical clinical advances, and prioritizes multidisciplinary work to improve how these symptoms are understood, detected, and treated.
Browse more opportunities from the same category: Education Health
Next opportunity: Research on the Cognitive Sequelae of Parkinsons Disease (R21)
Previous opportunity: Register Early and Other Important Information for Electronic Application Submission
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 033
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 033) also looked into and applied for these:
| Funding Opportunity |
|---|
| Established Investigator Award in Cancer Prevention and Control Apply for PAR 05 145 Funding Number: PAR 05 145 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Career Development Award to Promote Diversity (K01) Apply for PAR 06 220 Funding Number: PAR 06 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Clinical Scientist Award to Promote Diversity (K08) Apply for PAR 06 221 Funding Number: PAR 06 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mentored Patient Oriented Research Award to Promote Diversity (K23) Apply for PAR 06 222 Funding Number: PAR 06 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Translational Research in Integrative Behavioral Science (R24) Apply for PAR 06 357 Funding Number: PAR 06 357 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award (K07) Apply for PAR 06 381 Funding Number: PAR 06 381 Agency: National Institutes of Health Category: Education Health Funding Amount: $105,000 |
| Paul Calabresi Career Development Award For Clinical Oncology (K12) Apply for PAR 06 449 Funding Number: PAR 06 449 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The NCI Transition Career Development Award (K22) Apply for PAR 06 455 Funding Number: PAR 06 455 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) Apply for PA 07 002 Funding Number: PA 07 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20) Apply for PAR 07 230 Funding Number: PAR 07 230 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 07 346 Funding Number: PAR 07 346 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS International Training and Research Program (D43) Apply for PAR 07 348 Funding Number: PAR 07 348 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2009 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 09 011 Funding Number: RFA DA 09 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2009 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 09 044 Funding Number: PAR 09 044 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative and Applied Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 09 004 Funding Number: RFA CA 09 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Innovative and Applied Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 09 005 Funding Number: RFA CA 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Application and Use of Transformative Emerging Technologies in Cancer Research (R21) Apply for RFA CA 09 006 Funding Number: RFA CA 09 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Application and Use of Transformative Emerging Technologies in Cancer Research (R33) Apply for RFA CA 09 007 Funding Number: RFA CA 09 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 09 008 Funding Number: RFA CA 09 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) Apply for PAR 09 050 Funding Number: PAR 09 050 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 033", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.